Portage Biotech has shifted to a Toncoin (TON) treasury model to fund its cancer research initiatives. The company, which began this transition in September 2025, generates revenue by staking TON to secure the network and investing in projects within the Telegram ecosystem. A portion of these funds is dedicated to advancing cancer research. AlphaTON CEO Brittany Kaiser emphasized the potential of real-world asset tokenization (RWA) to decentralize scientific funding, aiming to eliminate traditional financial barriers. This innovative approach seeks to accelerate biomedical advancements by utilizing blockchain technology and staking income.